Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

ABSTRACT:

Background

Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.

Methods

In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmonary tuberculosis from 13 countries, we compared two 4-month rifapentine-based regimens with a standard 6-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol (control) using a noninferiority margin of 6.6 percentage points. In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival free of tuberculosis at 12 months.

Results

Among 2516 pa

SUBMITTER: Dorman SE 

PROVIDER: S-EPMC8282329 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature